{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:22:59Z","timestamp":1791026579547,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,9,15]],"date-time":"2012-09-15T00:00:00Z","timestamp":1347667200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1745-6215-13-168","type":"journal-article","created":{"date-parts":[[2012,9,15]],"date-time":"2012-09-15T14:14:27Z","timestamp":1347718467000},"source":"Crossref","is-referenced-by-count":140,"title":["Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial"],"prefix":"10.1186","volume":"13","author":[{"given":"Matthew R","family":"Sydes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh KB","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm D","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel W","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Amos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P","family":"Dearnaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordana","family":"Jovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair WS","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Martin","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Thalmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas D","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,9,15]]},"reference":[{"key":"1035_CR1","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1002\/sim.1430","volume":"22","author":"P Royston","year":"2003","unstructured":"Royston P, Parmar MKB, Qian W: Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer. Stat Med. 2003, 22: 2239-2256. 10.1002\/sim.1430.","journal-title":"Stat Med"},{"key":"1035_CR2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1745-6215-12-81","volume":"12","author":"P Royston","year":"2011","unstructured":"Royston P, Barthel FMS, Parmar MKB, Choodari-Oskooei B, Isham V: Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit. Trials. 2011, 12: 81-10.1186\/1745-6215-12-81.","journal-title":"Trials"},{"key":"1035_CR3","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1093\/jnci\/djn267","volume":"100","author":"MKB Parmar","year":"2008","unstructured":"Parmar MKB, Barthel F, Sydes M, Langley R, Kaplan R, Eisenhauer E, Brady M, James N, Bookman MA, Swart AM, Qian W, Royston P: Speeding up the evaluation of New agents in cancer. J Natl Canc Inst. 2008, 100: 1204-1214. 10.1093\/jnci\/djn267.","journal-title":"J Natl Canc Inst"},{"key":"1035_CR4","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.clon.2008.07.002","volume":"20","author":"N James","year":"2008","unstructured":"James N, Sydes M, Clarke N, Mason M, Dearnaley D, Anderson J, Popert R, Sanders K, Morgan R, Stansfeld J, Dwyer J, Masters J, Parmar MKB: STAMPEDE: systemic therapy for advancing or metastatic prostate cancer - a multi-Arm multi-stage randomised controlled trial. Clin Onc. 2008, 20: 577-581. 10.1016\/j.clon.2008.07.002.","journal-title":"Clin Onc"},{"key":"1035_CR5","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/j.1464-410X.2008.08034.x","volume":"103","author":"ND James","year":"2009","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Anderson J, Popert RJ, Sanders K, Morgan RC, Stansfeld J, Dwyer J, Masters J, Parmar MKB: Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. BJU Int. 2009, 103: 464-469. 10.1111\/j.1464-410X.2008.08034.x.","journal-title":"BJU Int"},{"key":"1035_CR6","unstructured":"http:\/\/www.stampedetrial.org ,"},{"key":"1035_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1745-6215-10-39","volume":"10","author":"MR Sydes","year":"2009","unstructured":"Sydes MR, Parmar MKB, James ND, Clarke NW, Dearnaley DP, Mason MD, Morgan RC, Sanders K, Royston P: Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. Trials. 2009, 10: 39-10.1186\/1745-6215-10-39.","journal-title":"Trials"},{"key":"1035_CR8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/1536867X0500500114","volume":"5","author":"FM-S Barthel","year":"2005","unstructured":"Barthel FM-S, Royston P, Babiker A: A menu-driven facility for complex sample size calculation in randomized controlled trials with a survival or a binary outcome: Update. Stata J. 2005, 5: 123-129.","journal-title":"Stata J"},{"key":"1035_CR9","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/1536867X0900900401","volume":"9","author":"FM-S Barthel","year":"2009","unstructured":"Barthel FM-S, Royston P, Parmar MKB: A menu-driven facility for sample-size calculation in novel multiarm, multistage randomized controlled trials with a time-to-event outcome. Stata J. 2009, 9: 505-","journal-title":"Stata J"},{"key":"1035_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1536867X1001000306","volume":"10","author":"P Royston","year":"2010","unstructured":"Royston P, Barthel FM: Projection of power and events in clinical trials with a time-to-event outcome. Stata J. 2010, 10: 1-9.","journal-title":"Stata J"},{"key":"1035_CR11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nrd1470","volume":"3","author":"I Kola","year":"2004","unstructured":"Kola I, Landis JR: Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov. 2004, 3: 711-715. 10.1038\/nrd1470.","journal-title":"Nat Rev Drug Discov"},{"key":"1035_CR12","first-page":"1295","volume":"331","author":"A Kumar","year":"2005","unstructured":"Kumar A, Soares H, Wells R, Clarke M, Hozo I, Bleyer A, Reaman G, Chalmers I, Djulbegovic B: Are experimental treatments for cancer in children superior to established treatments?. Observational study of randomised controlled trials by the Children's Oncology Group. BMJ. 2005, 331: 1295-","journal-title":"Observational study of randomised controlled trials by the Children's Oncology Group. BMJ"},{"key":"1035_CR13","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.1200\/JCO.2003.01.204","volume":"21","author":"TG Roberts Jr","year":"2003","unstructured":"Roberts TG, Lynch TJ, Chabner BA: The phase III trial in the era of targeted therapy: unraveling the \"go or no go\" decision. J Clin Oncol. 2003, 21: 3683-3695. 10.1200\/JCO.2003.01.204.","journal-title":"J Clin Oncol"},{"key":"1035_CR14","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1470-2045(12)70088-8","volume":"13","author":"ND James","year":"2012","unstructured":"James ND, Sydes MR, Mason MD, Clarke NW, Anderson J, Dearnaley DP, Dwyer J, Jovic G, Ritchie AWS, Russell JM, Sanders K, Thalmann GN, Bertelli G, Birtle AJ, O'Sullivan JM, Protheroe A, Sheehan D, Srihari N, Parmar MKB: Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol. 2012, 13: 549-558. 10.1016\/S1470-2045(12)70088-8.","journal-title":"Lancet Oncol"},{"key":"1035_CR15","doi-asserted-by":"crossref","unstructured":"James ND, Sydes MR, Mason MD, Clarke NW, Dearnaley DP, Dwyer J, Jovic G, Russell JM, Thalmann G, Parmar MKB: Celecoxib plus hormone therapy Vs hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE randomised controlled trial (MRC PR08). Eur J Cancer. 2011, 11-Suppl 2","DOI":"10.1016\/S0959-8049(11)70119-8"},{"key":"1035_CR16","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010, 376: 1147-1154. 10.1016\/S0140-6736(10)61389-X.","journal-title":"Lancet"},{"key":"1035_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010, 363: 411-422. 10.1056\/NEJMoa1001294.","journal-title":"N Engl J Med"},{"key":"1035_CR18","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S1470-2045(07)70147-X","volume":"8","author":"S Nilsson","year":"2007","unstructured":"Nilsson S, Franzen L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennernas B, Petersson U, Johannessen DC, Sokal M, Pigott K, Yachnin J, Garkavij M, Strang P, Harmenberg J, Bolstad B, Bruland OS: Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007, 8: 587-594. 10.1016\/S1470-2045(07)70147-X.","journal-title":"Lancet Oncol"},{"key":"1035_CR19","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S0140-6736(10)60172-9","volume":"375","author":"HI Scher","year":"2010","unstructured":"Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL: Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1\u20132 study. Lancet. 2010, 375: 1437-1446. 10.1016\/S0140-6736(10)60172-9.","journal-title":"Lancet"},{"key":"1035_CR20","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1126\/science.1168175","volume":"324","author":"C Tran","year":"2009","unstructured":"Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL: Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009, 324: 787-790. 10.1126\/science.1168175.","journal-title":"Science"},{"key":"1035_CR21","volume-title":"New Engl J Med","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller MDK: Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. New Engl J Med. 2012, 10.1056\/NEJMoa1207506. Published online 15-Aug-2012"},{"key":"1035_CR22","doi-asserted-by":"publisher","first-page":"4516","DOI":"10.1200\/JCO.2010.33.7741","volume":"29","author":"M Hussain","year":"2011","unstructured":"Hussain M, Smith MR, Sweeney C, Corn PG, Elfiky A, Gordon MS, Haas NB, Harzstark AL, Kurzrock R, Lara P, Lin C, Sella A, Small EJ, Spira AI, Vaishampayan UN, Vogelzang NJ, Scheffold C, Ballinger MD, Schimmoller F, Smith DC: Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial. J Clin Oncol. 2011, 29: 4516-10.1200\/JCO.2010.33.7741.","journal-title":"J Clin Oncol"},{"key":"1035_CR23","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1158\/1078-0432.CCR-10-0567","volume":"17","author":"G Attard","year":"2011","unstructured":"Attard G, Richards J, de Bono JS: New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res. 2011, 17: 1649-1657. 10.1158\/1078-0432.CCR-10-0567.","journal-title":"Clin Cancer Res"},{"key":"1035_CR24","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1200\/JCO.2009.25.9259","volume":"28","author":"DC Danila","year":"2010","unstructured":"Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, Larson SM, Schwartz LH, Fleisher M, Scher HI: Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 2010, 28: 1496-1501. 10.1200\/JCO.2009.25.9259.","journal-title":"J Clin Oncol"},{"key":"1035_CR25","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1200\/JCO.2009.24.6819","volume":"28","author":"AH Reid","year":"2010","unstructured":"Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, Dearnaley D, Swennenhuis JF, Terstappen LW, Lee G, Kheoh T, Molina A, Ryan CJ, Small E, Scher HI, de Bono JS: Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol. 2010, 28: 1489-1495. 10.1200\/JCO.2009.24.6819.","journal-title":"J Clin Oncol"},{"key":"1035_CR26","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1200\/JCO.2009.24.1281","volume":"28","author":"CJ Ryan","year":"2010","unstructured":"Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ: Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010, 28: 1481-1488. 10.1200\/JCO.2009.24.1281.","journal-title":"J Clin Oncol"},{"key":"1035_CR27","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Hagg CM, Scher HI, COU-AA-301 Investigators, COU-AA-301 Investigators: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011, 364: 1995-2005. 10.1056\/NEJMoa1014618.","journal-title":"N Engl J Med"},{"key":"1035_CR28","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature09339","volume":"467","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Ashworth A: Translating cancer research into targeted therapeutics. Nature. 2010, 467: 543-549. 10.1038\/nature09339.","journal-title":"Nature"},{"key":"1035_CR29","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1200\/JCO.2010.32.1752","volume":"29","author":"HI Scher","year":"2011","unstructured":"Group obotC-A-S, Scher HI, Logothetis C, Molina A, Goodman OB, Sternberg CN, Chi KN, Kheoh TS, Haqq CM, Fizazi K, Bono JSD: Improved survival outcomes in clinically relevant patient subgroups from COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-based chemotherapy. J Clin Oncol. 2011, 29: 4-10.1200\/JCO.2010.32.1752.","journal-title":"J Clin Oncol"},{"key":"1035_CR30","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0140-6736(08)61815-2","volume":"373","author":"A Widmark","year":"2009","unstructured":"Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JA, Tasdemir I, Hoyer M, Wiklund F, Fossa SD: Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7\/SFUO-3): an open randomised phase III trial. Lancet. 2009, 373: 301-308. 10.1016\/S0140-6736(08)61815-2.","journal-title":"Lancet"},{"key":"1035_CR31","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1016\/S0140-6736(11)61095-7","volume":"378","author":"P Warde","year":"2011","unstructured":"Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, Gospodarowicz M, Sanders K, Kostashuk E, Swanson G, Barber J, Hiltz A, Parmar MKB, Sathya J, Anderson J, Hayter C, Hetherington J, Sydes MR, Parulekar W, for the NCIC CTG PR.3\/MRC UK PR07 investigators, for the NCIC CTG PR.3\/MRC UK PR07 investigators: Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 2011, 378: 2104-2111. 10.1016\/S0140-6736(11)61095-7.","journal-title":"Lancet"},{"key":"1035_CR32","volume-title":"Clinical Trials: A Practical Approach","author":"S Pocock","year":"1983","unstructured":"Pocock S: Clinical Trials: A Practical Approach. 1983, New York: Wiley"},{"key":"1035_CR33","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/cpt1974155443","volume":"15","author":"DR Taves","year":"1974","unstructured":"Taves DR: Minimization: a new method of assigning patients to treatment and control groups. Clin Pharmacol Ther. 1974, 15: 443-453.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1745-6215-13-168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1745-6215-13-168\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1745-6215-13-168","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T00:03:18Z","timestamp":1562198598000},"score":1,"resource":{"primary":{"URL":"http:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/1745-6215-13-168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,15]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["1035"],"URL":"https:\/\/doi.org\/10.1186\/1745-6215-13-168","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,15]]},"article-number":"168"}}